Brief: Ault Alliance Announces Alzamend Neuro Has Initiated Phase I/Iia Trial For Its Immunotherapy Vaccine (Alzn002)
04/04/2023 11:37
April 4 (Reuters) - Alzamend Neuro Inc ALZN.O :
* AULT ALLIANCE ANNOUNCES ALZAMEND NEURO HAS INITIATED ITS
PHASE
I/IIA TRIAL FOR ITS IMMUNOTHERAPY VACCINE (ALZN002) TO TREAT
MILD TO MODERATE DEMENTIA OF THE ALZHEIMER’S TYPE
* AULT ALLIANCE INC - BENEFICIALLY OWNS APPROXIMATELY 11.3
MILLION
SHARES OF ALZAMEND
* AULT ALLIANCE - ALZAMEND EXPECTS TO INITIATE LARGER PHASE
IIB
EFFICACY & SAFETY CLINICAL TRIAL WITHIN 3 MONTHS OF RECEIVING
DATA FROM INITIAL TRIAL
Source text for Eikon: ID:nBw7BtQNTa
Further company coverage: ALZN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview